<DOC>
	<DOCNO>NCT02279563</DOCNO>
	<brief_summary>This study evaluate equivalence generic Azelastine Hydrochloride Fluticasone Propionate Nasal Spray market drug , Dymista™ Nasal Spray , treatment seasonal allergic rhinitis , evaluate safety tolerability generic Azelastine Hydrochloride Fluticasone Propionate nasal spray compare Dymista™ nasal spray .</brief_summary>
	<brief_title>A Study Comparing Bioequivalence Azelastine Hydrochloride Fluticasone Propionate Nasal Spray ( Apotex , Inc. ) That Dymista™ Nasal Spray ( Meda Pharmaceuticals , Inc. ) Treatment Seasonal Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Azelastine</mesh_term>
	<criteria>Subjects meet follow criterion eligible inclusion study : 1 . Subjects provide write informed consent . 2 . Subjects able read understand English . 3 . Males female , 18 65 year old , inclusive . 4 . If subject female childbearing potential , pregnant ( confirm negative urine pregnancy test ) lactating . Females childbearing potential agree use reliable birth control measure throughout study , define abstinence use effective method birth control ( double barrier [ female subject 's partner use condom female subject use diaphragm , contraceptive sponge , spermicide , intrauterine device ] , use hormonal contraceptive [ oral , patch , insert skin inject muscle ] ) . Female subject use oral contraceptive levonorgestrel implant require start method least 90 day prior screen visit . A female childbearing potential define female experienced menarche , undergone successful surgical sterilization ( hysterectomy , bilateral oophorectomy ovariectomy , bilateral tubal ligation salpingectomy ) postmenopausal least 1 year . 5 . At least 2year reliable medical history consistent SAR , define symptom present previous two grass and/or pollen season . 6 . Positive skin test within 12 month screen least one currently present seasonal allergen geographical area predictable allergen season ( eg , birch pollen , ragweed , Mountain Cedar , etc ) minimum skin test response 3 mm great negative control , positive test histamine , also define response 3 mm great negative control . 7 . Was capable tolerate intranasal application study drug . 8 . No clinically significant result screen physical examination , nasal examination , medical history . 9 . Was willing able comply requirement protocol available full duration study , plan travel outside pollen area substantial portion ( &gt; 48 hour ) study period . 10 . Was , Investigator 's judgment ( exposure allergen ) , expect require treatment throughout entire study period . Subjects meet follow criterion exclude study : 1 . Signs symptoms nasal polyp , deviate septum , condition ( include nasal pierce within previous 3 month ) , opinion Investigator , may result erroneous study data . 2 . Underwent nasal surgery nasal trauma within 3 month Visit 1 ( screen ) . 3 . Had active respiratory condition include , limit , acute exacerbate chronic sinusitis , abnormal sinus radiograph , upper low respiratory tract infection , rhinitis medicamentosa . 4 . Had PAR require expect require active PAR treatment study period . 5 . Had respiratory tract infection ( include otitis medium streptococcus ) require antibiotic treatment within 2 week Visit 1 ( screen ) . 6 . Used prohibited medication prior start singleblind , placebo leadin visit ( Visit 2 ) within time period specify protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>